BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12383370)

  • 21. Role of P53 and MDM2 in treatment response of human germ cell tumors.
    Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
    J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accumulation of MDM2 in pleomorphic xanthoastrocytomas.
    Matsumoto K; Suzuki SO; Fukui M; Iwaki T
    Pathol Int; 2004 Jun; 54(6):387-91. PubMed ID: 15144396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin-1-like immunoreactivity is expressed in human reactive astrocytes.
    Jiang MH; Höög A; Ma KC; Nie XJ; Olsson Y; Zhang WW
    Neuroreport; 1993 Jul; 4(7):935-7. PubMed ID: 8369484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
    J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
    Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
    J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
    Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
    Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes.
    Schittenhelm J; Mittelbronn M; Nguyen TD; Meyermann R; Beschorner R
    Brain Pathol; 2008 Jul; 18(3):344-53. PubMed ID: 18371184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship of PTEN, Mdm2 and p53 expression in astrocytoma].
    Zhong XY; Sun YH; Chen YX
    Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):478-81. PubMed ID: 14575575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of p53 and MDM2 proteins in cervical neoplasia.
    Lukás Z; Vojtĕsek B; Anton M; Picksley SM; Kubálek V
    Folia Biol (Praha); 1995; 41(3-4):197-9. PubMed ID: 7589715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
    PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
    Hao XP; Günther T; Roessner A; Price AB; Talbot IC
    Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.